159 related articles for article (PubMed ID: 26001206)
1. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Cheng H; Shang Y; Jiang L; Shi TL; Wang L
Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Liu J; Wang LN; Jia JP
Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone for the treatment of Alzheimer's disease.
Galimberti D; Scarpini E
Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S
Biol Pharm Bull; 2018; 41(7):1017-1023. PubMed ID: 29962398
[TBL] [Abstract][Full Text] [Related]
5. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
6. Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in alzheimer's disease mice model.
El-Din SS; Abd Elwahab S; Rashed L; Fayez S; Aboulhoda BE; Heikal OA; Galal AF; Nour ZA
Metab Brain Dis; 2021 Oct; 36(7):1903-1915. PubMed ID: 34043126
[TBL] [Abstract][Full Text] [Related]
7. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-γ agonistic property.
Singh B; Sharma B; Jaggi AS; Singh N
J Renin Angiotensin Aldosterone Syst; 2013 Jun; 14(2):124-36. PubMed ID: 23060470
[TBL] [Abstract][Full Text] [Related]
8. Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis.
Yang J; Shi X; Wang Y; Ma M; Liu H; Wang J; Xu Z
J Alzheimers Dis; 2023; 96(3):927-945. PubMed ID: 37927258
[TBL] [Abstract][Full Text] [Related]
9. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
Gupta R; Gupta LK
Pharmacol Biochem Behav; 2012 Aug; 102(2):184-90. PubMed ID: 22503969
[TBL] [Abstract][Full Text] [Related]
10. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer's Disease.
Kotha S; B S; Kulkarni VM; S RS; B HK; R H
J Biomol Struct Dyn; 2021 Apr; 39(6):2210-2229. PubMed ID: 32216605
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
Landreth G
Curr Alzheimer Res; 2007 Apr; 4(2):159-64. PubMed ID: 17430241
[TBL] [Abstract][Full Text] [Related]
12. [Alzheimer's disease].
Hanyu H; Sato T
Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105
[TBL] [Abstract][Full Text] [Related]
13. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
[TBL] [Abstract][Full Text] [Related]
14. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease.
Hanyu H; Sato T; Sakurai H; Iwamoto T
J Am Geriatr Soc; 2010 May; 58(5):1000-1. PubMed ID: 20722838
[No Abstract] [Full Text] [Related]
15. Lack of genetic associations between PPAR-γ gene rs1801282 polymorphism and Alzheimer's disease in general population: a meta-analysis.
Wu Y; Wu Q; Zhang H; Chen C; Chen G; Yang H; Qin D; Fu H
Gene; 2015 Jun; 563(2):120-4. PubMed ID: 25770052
[TBL] [Abstract][Full Text] [Related]
16. An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.
Chamberlain S; Gabriel H; Strittmatter W; Didsbury J
J Alzheimers Dis; 2020; 73(3):1085-1103. PubMed ID: 31884472
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.
Landreth G
Exp Neurol; 2006 Jun; 199(2):245-8. PubMed ID: 16733054
[No Abstract] [Full Text] [Related]
18. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
Landreth G; Jiang Q; Mandrekar S; Heneka M
Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
[TBL] [Abstract][Full Text] [Related]
20. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
